Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.

OBJECTIVE The aim of this study was to compare apoptotic and antiproliferative effects of gonadotropin-releasing hormone analogues and their combination with octeotide on endometrioid endometrial cancer cell lines. MATERIAL AND METHOD Women diagnosed with endometrioid adenocarcinoma at the department of Gynecology and Obstetric of Kocaeli University Medical School were included in this research. Endometrium cancer cell lines obtained from three patients were used for this study. After trypsinization in 0.5% in calcium magnesium, free phosphate buffer solution (CMFPBS) cells were seeded on glass slides in 24-well plates containing DMEM-F12 medium and 10% fetal calf serum as culture medium. Cells were incubated for 24 hours at 37ºC in 5% CO2. GnRH agonist leuprolide (Lucrin 1 μmol/L), GnRH antagonist ganirelix (Orgalutran 1 μmol/L), leuprolide with octreotide (Sandostatin 10-6 mol/L), ganirelix with octreotide and no drug were added to the wells. Apoptosis and cells proliferations were evaluated after 12, 24, 48 and 72(th) hours of incubation. The percentage of apoptotic cells was evaluated by TdT mediated biotin-dUTP nick-end labeling (TUNEL) method; cell proliferation was assessed by bromodeoxyuridine (BrdU) incorporation. RESULTS Apoptotic index in grade I EEC cell line among ganirelixoctreotide treated cells and leuprolide-octreotide combination therapy were respectively higher than the untreated control (p<0.001, p=0.001). The number of apoptotic cells in grade II EEC cell line among leuprolide-octreotide and leuprolide were significantly (p<0.001, p<0.001) higher than in controls. In grade III EEC cell line, the number of TUNEL positive cells among leuprolide, ganirelix and ganirelixoctreotide therapiy groups were significantly higher than in untreated control. Time dependent antiproliferative effect was obtained with leuprolide and leuprolide-octreotide in grade I EEC (p<0.001, p<0.001). Grade II EEC cell line is not influenced by hormonotherapies. However, the antiproliferative effect was obtained with ganirelix, leuprolide and leuprolide-octreotide in grade III cell line. CONCLUSION GnRH analogues appears to have a direct effect, enhancing the apoptotic index and decreasing the cell proliferation in endometrial adenocancer cell lines.

[1]  K. Ushijima [Hormonal treatment of endometrial cancer]. , 2012, Nihon rinsho. Japanese journal of clinical medicine.

[2]  P. Leung,et al.  Reproductive Biology and Endocrinology Gonadotropin-releasing Hormone (gnrh)-i and Gnrh-ii Induce Cell Growth Inhibition in Human Endometrial Cancer Cells: Involvement of Integrin Beta3 and Focal Adhesion Kinase Background , 2022 .

[3]  P. Leung,et al.  Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha. , 2009, Cancer research.

[4]  N. Park,et al.  Gonadotropin-releasing Hormone Receptor Expression in Endometrial Cancer , 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[5]  J. Schmitt,et al.  Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. , 2003, Gynecologic oncology.

[6]  T. Bäckström,et al.  Apoptosis, proliferation, and hormone receptors in endometrial carcinoma: results depending on methods of analysis. , 2003, International journal of oncology.

[7]  チェン チェン,et al.  Gonadotropin-releasing hormone receptor antagonist , 2002 .

[8]  G. Emons,et al.  Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. , 2002, The Journal of clinical endocrinology and metabolism.

[9]  E. Latta,et al.  PTEN mutations and evolving concepts in endometrial neoplasia , 2002, Current opinion in obstetrics & gynecology.

[10]  G. Emons,et al.  Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. , 2002, American journal of obstetrics and gynecology.

[11]  M. Paglierani,et al.  Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. , 2000, Cancer letters.

[12]  Y. Taketani,et al.  Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. , 1999, American journal of obstetrics and gynecology.

[13]  M. Arends Apoptosis in the endometrium , 1999, Histopathology.

[14]  V. Müller,et al.  Effects of LHRH-analogues on mitogenic signal transduction in cancer cells 1 1 Proceedings of the 13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology “Recent Advances in Steroid Biochemistry & Molecular Biology” Monaco 25–28 May 1997. , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  A. Schally,et al.  Mechanisms of Antineoplastic Action of Somatostatin Analogs , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[16]  T. Tamaya,et al.  Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. , 1998, The Journal of clinical endocrinology and metabolism.

[17]  T. Furui,et al.  Gonadotropin‐releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types , 1994, Cancer.

[18]  T. Furui,et al.  Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. , 1994, Gynecologic oncology.

[19]  A. Schally,et al.  Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis. , 1994, American journal of obstetrics and gynecology.

[20]  A. Schally,et al.  High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. , 1993, The Journal of clinical endocrinology and metabolism.

[21]  G. Emons,et al.  Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH‐agonists in ovarian cancer , 1992, Acta obstetricia et gynecologica Scandinavica. Supplement.

[22]  M. Slevin,et al.  A new treatment for endometrial cancer with gonadotrophin releasing‐hormone analogue , 1991, British journal of obstetrics and gynaecology.

[23]  R. Sylvester,et al.  Zoladex and Flutamide Versus Orchiectomy in the Treatment of Advanced Prostatic Cancer , 1990, Cancer.

[24]  R. Santen,et al.  Treatment of breast cancer with gonadotropin-releasing hormone. , 1986, Endocrine reviews.